Last month, Abeona Therapeutics resubmitted a Biologics License Application (BLA) to the FDA for its investigational RDEB treatment. We are thankful to the people who volunteer for research and clinical trials. Your time and commitment bring us one step closer to helping those in need. #AbeonaTherapeutics #AddressingUnmetNeeds #PatientVoices #GeneandCellTherapy #RDEB #PatientInspiration #WeFightEB
关于我们
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL? trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
- 网站
-
https://www.abeonatherapeutics.com
Abeona Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cleveland，OH
- 类型
- 上市公司
- 创立
- 2015
- 领域
- Gene Therapy、Biotechnology、Cell Therapy、Rare Disease、Epidermolysis Bullosa、Pediatric Rare Diseases和manufacturing
地点
Abeona Therapeutics员工
-
Jim Geers, MBA, PMP
Senior Regulatory Consultant, Regulatory Affairs Program Management
-
Mark Alvino
Founder & CEO at Bridge Back Foundation
-
Alison Hardgrove
-
Bernhardt (Bernie) Zeiher, MD, FCCP, FACP
Board Member | Strategic Advisor | Physician Executive | Former Chief Medical Officer | Biopharmaceutical Industry Expert
动态
-
The FDA has accepted Abeona’s BLA resubmission for prademagene zamikeracel (pz-cel) in recessive dystrophic epidermolysis bullosa (RDEB) with a PDUFA target action date of April 29, 2025. Read about our latest progress here: https://bit.ly/40I4ukY. #SevereDEB #RDEB #AbeonaTherapeutics
-
The FDA has accepted Abeona’s BLA resubmission for prademagene zamikeracel (pz-cel) in recessive dystrophic epidermolysis bullosa (RDEB) with a PDUFA target action date of April 29, 2025. Read about our latest progress here: https://bit.ly/40I4ukY. #SevereDEB #RDEB #AbeonaTherapeutics
Home
https://abeonatherapeutics.com
-
Today, Abeona Therapeutics announced the resubmission of our BLA to the FDA for prademagene zamikeracel (pz-cel), our investigational autologous cell-based gene therapy, as a potential new treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). Read about our latest progress here: https://lnkd.in/esy6_iZU. #SevereDEB #RDEB #AbeonaTherapeutics
-
-
?? Epidermolysis Bullosa Awareness week is underway! Abeona Therapeutics supports those affected by this condition. Our commitment to developing a treatment to address the unmet needs of those living with RDEB is the drive behind our mission. ???? ?? Together we raise awareness. ?? Together we foster understanding. #EBAwarenessWeek2024 #EverydayisEBAwareness #AbeonaTherapeutics #PatientVoices #KnowledgeIsContagious #GeneAndCellTherapy #RDEB #PatientInspiration #WeFightEB
-
Abeona Therapeutics is looking forward to celebrating ???? Dr. Anna Bruckner at this year's#debraBenefit. We are a proud sponsor of #debraBenefit2024. See you in California! #EBAwareness #AbeonaTherapeutics #JouniUittoImpactAward #wefightEB #EBAwarenessWeek
? We’re thrilled to announce that Dr. Anna Bruckner of Children has been named the recipient of the 2024 Jouni Uitto Impact Award! She’ll be honored at this year’s #debraBenefit. Just 1 WEEK to go until our biggest fundraising event of the year on Saturday, October 26, at SoFi Stadium in Los Angeles! ??? Read more about Dr. Bruckner’s incredible contributions and secure your tickets to the #debraBenefit today at https://lnkd.in/gM_m6Ufa
-
-
Epidermolysis Bullosa, or EB for short, is an extremely challenging and life-threatening genetic skin disorder that affects kids from birth. We are honored to support EB Research Partnership and work alongside the entire EB community on our journey towards treatments and ultimately a cure. ?????? This #EBAwarenessWeek, we hope you’ll take a few minutes to learn about EB and how you can support those living with the disease. #WingsofChange
This #EBAwarenessWeek, we need your help to make a BIG impact. Get involved, spread EB awareness, donate, and help us raise funds for life-saving research. ?? ?? ?? Every dollar donated to our #WingsofChange campaign will be DOUBLED up to $250,000. No action and no dollar amount is too small. We can ALL make a difference in the fight against EB. Join us. https://lnkd.in/ed4G_fCP
-
Living with Epidermolysis Bullosa (EB) comes with unique challenges including silent stares from strangers, bouts of anxiety and so much more. Listen to their voices and let's learn from their experiences. #patientvoices #nowyouknow #geneandcelltherapy #rdeb #abeonatherapeutics #patientinspiration #wefightEB
-
We were honored to participate in this year’s debra of America Care Conference. Thank you to everyone who stopped by our booth, attended our session, and shared their stories with us. Our team is still energized from meeting and connecting with the brave people living with Epidermolysis Bullosa. Abeona Therapeutics remains committed to making a difference in the lives of those affected by RDEB. Your strength and resilience continue to drive our mission. #patientcare #cellandgenetherapy #connectingwithEB #RDEB #abeonatherapeutics #innovation #wefightEB #patientinspiration
-
??Watch and see just how cool scientists are. At Abeona Therapeutics, our mission is driven by the incredible strength and resilience of the patients we aim to help. Every member of our team is fueled by the bravery of those living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) ???? #Geneandcelltherapy #RDEB #Abeonatherapeutics #Innovation #Scienceinaction #WeFightEB #Behindthescenes #Patientinspiration